1. Introduction

Regulatory approval for diagnostic tools is an essential component of biotechnology and healthcare law. Diagnostic tools help identify diseases, detect infections, analyse genetic abnormalities, monitor medical conditions and support clinical decision-making.

These tools include:

In-vitro diagnostic (IVD) test kits.

PCR and molecular diagnostic systems.

Genetic testing and DNA analysis equipment.

Blood glucose and pregnancy testing devices.

Cancer biomarker detection systems.

Laboratory reagents and diagnostic instruments.

AI-based diagnostic software.

Rapid infectious disease detection kits.

In Morocco, diagnostic tools are regulated through a combination of medical-device legislation, in-vitro diagnostic reagent legislation, pharmaceutical regulation and laboratory standards.

The principal legal distinction is between medical devices and in-vitro diagnostic reagents. They may be subject to different approval and registration procedures.

The regulatory framework aims to ensure that diagnostic products are scientifically reliable, safe, effective for their intended purpose and manufactured according to appropriate quality standards.

2. Legal framework governing diagnostic tools in Morocco

The principal legislation includes the following:

These instruments are identified in the Moroccan Ministry of Health's official regulatory framework.

sante.gov.ma+1

A. Law No. 11-08: In-vitro diagnostic reagents

Law No. 11-08 establishes the specific legal framework for reagents used in in-vitro diagnosis.

It is particularly important for:

Blood testing reagents.

Microbiological diagnostic reagents.

Immunological testing kits.

Genetic testing reagents.

Biochemical diagnostic materials.

Laboratory controls and standards.

The regulatory objective is to ensure that reagents used to generate diagnostic results meet appropriate standards of quality and reliability.

B. Law No. 84-12: Medical devices

Law No. 84-12, promulgated by Dahir No. 1-13-90 of 30 August 2013, governs medical devices in Morocco.

Article 3 recognises diagnosis as one of the purposes for which medical devices may be used.

Article 12 establishes the requirement for a prior registration certificate before a medical device can be placed on the Moroccan market.

Article 14 requires an administrative and technical application dossier demonstrating the device's performance and compliance with essential requirements.

Article 15 addresses clinical investigations or evaluation of existing clinical data.

Articles 16 and 20 establish continuing responsibilities and the separate regulatory treatment of associated products.

Ma Loi+3

3. Regulatory authorities responsible for approval

The Moroccan regulatory system involves health authorities and specialised institutions.

A. Moroccan Agency for Medicines and Health Products (AMMPS)

The AMMPS plays an important role in the regulation of health products, including medical devices and diagnostic reagents.

Its responsibilities include:

Product registration and regulatory oversight.

Assessment of relevant technical documentation.

Monitoring compliance with applicable standards.

Supporting quality and safety surveillance.

Regulatory action concerning non-compliant products.

B. Ministry of Health and Social Protection

The Ministry provides the legislative and administrative framework for medical products and diagnostic services.

C. National Consultative Commission for Medical Devices

Under Law No. 84-12, the National Consultative Commission participates in the medical-device registration process.

The statutory framework therefore combines technical assessment with administrative decision-making.

4. Procedure for obtaining regulatory approval

The approval process generally involves the following stages.

Stage 1: Classification of the diagnostic product

The manufacturer or importer must first determine the legal category of the product.

For example:

Correct classification is important because a product cannot automatically use the approval pathway of another category.

Stage 2: Establishment registration or declaration

Under Article 7 of Law No. 84-12, establishments involved in manufacturing, importing, exporting or distributing medical devices must make the prescribed declaration to the administration before commencing their activities.

This requirement helps regulators identify responsible economic operators and establish accountability for products entering the market.

AMMPS+1

Stage 3: Submission of technical documentation

Applicants must prepare the appropriate administrative and technical documentation.

The dossier may include:

Manufacturer identification and legal documentation.

Product description and intended purpose.

Technical specifications.

Manufacturing information.

Quality-management documentation.

Analytical and performance-validation reports.

Safety and risk-assessment reports.

Clinical performance evidence, where applicable.

Labelling and instructions for use.

Country-of-origin regulatory status.

Batch-testing and quality-control information.

The precise documentation depends on the applicable product category and regulatory procedure.

Stage 4: Scientific and performance evaluation

Diagnostic tools must demonstrate that they perform reliably for their intended use.

Important assessment criteria include:

Analytical sensitivity.

Analytical specificity.

Diagnostic sensitivity.

Diagnostic specificity.

Accuracy and reproducibility.

Detection limits.

Interference and cross-reactivity.

Stability and shelf life.

Reliability across different patient populations.

For genetic diagnostic products, regulators may also need to consider the validity of genetic markers, population-specific performance and the risk of misleading interpretations.

Stage 5: Clinical evaluation

Under Article 15 of Law No. 84-12, registration of medical devices requires either an appropriate clinical investigation or an evaluation of existing clinical data through scientific literature where the applicant establishes equivalence with the relevant device.

The evaluation must help establish performance under normal conditions of use, the benefit-risk relationship and potential adverse effects.

Ma Loi+1

For IVD products, the specific requirements must also be considered under Law No. 11-08 and its implementing decree.

Stage 6: Registration certificate

Article 12 of Law No. 84-12 makes prior registration a condition for placing covered medical devices on the Moroccan market.

The application is considered through the relevant administrative process, including consultation with the National Consultative Commission for Medical Devices.

Approval must not be confused with customs clearance, an establishment declaration or foreign regulatory certification. These are distinct legal matters.

Stage 7: Post-market surveillance

Regulatory responsibility does not end when a diagnostic tool receives approval.

Manufacturers, importers and other responsible operators must address:

Product defects.

False-positive and false-negative results.

Unexpected diagnostic failures.

Adverse incidents.

Batch contamination.

Software-related errors.

Product recalls and corrective measures.

Morocco's AMMPS also maintains specific vigilance systems, including réactovigilance for diagnostic reagents and matériovigilance for medical devices.

AMMPS+1

5. Clinical and scientific standards for diagnostic approval

The reliability of a diagnostic tool is a central legal consideration.

Consider a PCR test designed to detect a viral infection.

The manufacturer should establish that:

The test detects the intended genetic target.

The test does not produce unacceptable cross-reactions.

The test performs consistently across different samples.

The test has an established detection limit.

The instructions correctly explain sample collection and interpretation.

The results can be reproduced under normal laboratory conditions.

A diagnostic device that produces unreliable results can cause incorrect treatment, delayed diagnosis and unnecessary medical intervention.

Consequently, regulatory approval is not simply a commercial licensing exercise. It is also a mechanism for protecting patients' rights, public health and the integrity of medical decision-making.

6. Special regulatory issues involving AI-based diagnostic tools

Modern diagnostic systems increasingly incorporate artificial intelligence and machine-learning algorithms.

Examples include:

AI-based cancer detection.

Automated radiological interpretation.

AI-supported genetic disease prediction.

Automated pathology analysis.

Predictive diagnostic software.

Machine-learning systems for infectious disease detection.

These technologies create additional regulatory questions.

A. Algorithmic accuracy

The manufacturer must demonstrate that the system performs reliably for its intended clinical purpose.

B. Bias and discrimination

A diagnostic algorithm trained primarily on one population may produce less reliable results for another population.

C. Explainability

Healthcare professionals should receive adequate information about the system's limitations and the circumstances in which its output should not be relied upon.

D. Software updates

A significant modification to the algorithm may change its diagnostic performance and potentially require regulatory reassessment.

E. Data protection

Genetic, medical and biometric information must be handled in accordance with applicable privacy and data-protection requirements.

AI diagnostic software should therefore be assessed according to its intended medical function, rather than assuming that every ordinary software product is a medical device.

7. Regulatory exemptions and emergency approval

Law No. 84-12 provides certain exceptions to ordinary registration requirements.

Article 13 addresses specified categories, including:

Experimental medical devices intended for biomedical research.

Certain devices prescribed for identified patients but not marketed in Morocco.

Custom-made medical devices.

Samples imported for evaluation before registration.

Certain devices intended for scientific exhibitions.

These exceptions do not mean that the products are automatically authorised for ordinary commercial distribution. Specific administrative authorisation may still be required.

Article 21 also provides an exceptional mechanism for placing medical devices on the market or putting them into service when public-health needs and an emergency justify it, subject to the statutory conditions.

Ma Loi+1

8. Important case laws and judicial interpretation

Moroccan case law specifically concerning diagnostic-tool approval is relatively limited. However, judicial decisions concerning medical-device registration provide important principles for diagnostic equipment and related products.

Case 1: Court of Appeal of Commerce, Casablanca (13 December 2022)

Case reference: Decision No. 5633, Case No. 2022/8202/3776.

Legal issue: Responsibility for obtaining medical-device registration in Morocco.

Facts:

A dispute arose between a foreign medical-device manufacturer and its Moroccan importer-distributor.

The distributor argued that it could not legally market the products because the foreign manufacturer had failed to provide the technical documentation required for registration under Law No. 84-12.

The dispute concerned unpaid commercial invoices and the allocation of regulatory responsibilities.

Judicial reasoning:

The Court of Cassation, in Decision No. 383/1 of 9 June 2022, held that the obligation to obtain the registration certificate under Article 12 rested on the entity importing and distributing the products in Morocco, rather than the foreign manufacturer that did not manufacture the products inside Morocco.

Following remittal, the Casablanca Court of Appeal applied that legal interpretation and upheld the commercial judgment.

Legal principle:

The Moroccan importer-distributor bears the statutory responsibility for obtaining the relevant registration certificate.

Relevance to diagnostic tools:

This decision is particularly important for foreign manufacturers exporting PCR machines, diagnostic equipment and laboratory systems to Morocco.

It demonstrates that foreign manufacturers and Moroccan importers should clearly allocate responsibility for technical documentation, product registration and regulatory cooperation in their distribution contracts.

Source: Casablanca Commercial Court of Appeal decision, 13 December 2022.

Case 2: Court of Cassation, Morocco (9 June 2022)

Case reference: Decision No. 383/1, Commercial Case No. 875/3/3/2020.

Legal issue: Interpretation of Article 12 of Law No. 84-12.

Facts:

The dispute concerned the registration of medical products supplied by a foreign manufacturer to a Moroccan distributor.

The lower appellate court had incorrectly allocated the registration obligation to the foreign manufacturer.

Judgment:

The Court of Cassation quashed the earlier appellate decision because the interpretation of Article 12 was inconsistent with its statutory wording.

It clarified that the entity importing and distributing medical devices within Morocco must obtain the registration certificate.

Legal principle:

Regulatory obligations must be allocated according to the actual statutory language and the role performed by the relevant commercial entity.

Relevance to diagnostic tools:

This principle applies when determining which party must secure the necessary regulatory documentation for imported diagnostic equipment falling within the medical-device framework.

It also highlights the importance of distinguishing the manufacturer's obligation to supply technical evidence from the importer's obligation to obtain domestic registration.

Source: Moroccan medical-device legislation and associated judicial decision.

Case 3: European Court of Justice – Boston Scientific Medizintechnik GmbH v AOK Sachsen-Anhalt

Case references: Joined Cases C-503/13 and C-504/13, judgment of 5 March 2015.

Legal issue: Medical-device safety and the concept of a potential risk to patients.

Facts:

The dispute concerned implanted medical devices in which certain product batches presented a potential safety risk.

Judicial reasoning:

The Court examined the safety requirements applicable to medical devices and the circumstances in which products may be considered defective because of potential risks.

Legal principle:

Medical-device safety must be assessed with regard to patient protection, including risks that may justify preventive action.

Relevance to diagnostic tools:

Although this case concerned implantable devices rather than diagnostic equipment, its reasoning is relevant to regulatory risk management.

For example, diagnostic devices producing potentially dangerous incorrect results may require corrective action, safety warnings or withdrawal.

This is comparative European jurisprudence, not binding Moroccan precedent.

Source: CJEU, Boston Scientific, Case C-503/13.

Case 4: European Court of Justice – Medipac-Kazantzidis

Case reference: Case C-6/05, judgment of 14 June 2007.

Legal issue: Compliance with medical-device safety requirements and public procurement.

Judgment:

The Court considered the legal significance of conformity requirements and the circumstances in which public authorities may question medical-device compliance.

Legal principle:

Public procurement decisions involving medical devices must respect the applicable regulatory framework and cannot disregard the prescribed conformity procedures without appropriate legal justification.

Relevance to diagnostic tools:

The decision is relevant when hospitals and public healthcare institutions purchase diagnostic equipment.

Purchasing authorities should consider regulatory status, conformity documentation, technical performance and patient safety.

This is also comparative European jurisprudence rather than binding Moroccan law.

9. Liability for unauthorised diagnostic tools

Unauthorised diagnostic products may create several forms of legal liability.

For example, if a Moroccan importer distributes an unregistered diagnostic device and the device produces inaccurate results, several legal questions may arise:

Was the product legally registered?

Did the manufacturer provide accurate technical documentation?

Did the importer comply with applicable registration requirements?

Was the diagnostic tool appropriately validated?

Did the laboratory follow proper procedures?

Did the inaccurate result cause identifiable patient harm?

The answers determine the applicable administrative, contractual, professional or civil liability.

10. Recent regulatory development: Registration of 575 IVD reagents

An important development occurred on 27 March 2026.

The Moroccan Agency for Medicines and Health Products announced the registration of 575 in-vitro diagnostic reagents, following a meeting of the National Consultative Commission on 26 March 2026.

This announcement demonstrates the practical importance of regulatory registration for diagnostic products in Morocco.

It also reflects the government's objective of improving access to reliable diagnostic products and strengthening oversight of the health-products sector.

AMMPS+1

11. Major regulatory challenges

The Moroccan regulatory system faces several important challenges.

1. Scientific validation: New diagnostic technologies require reliable analytical and clinical performance evidence.

2. Imported technology: Foreign manufacturers and Moroccan distributors must coordinate documentation and registration responsibilities.

3. Genetic diagnostics: Genetic tests raise additional concerns involving privacy, discrimination and interpretation of genetic information.

4. AI-based testing: Algorithmic changes can affect diagnostic accuracy and require appropriate regulatory oversight.

5. Laboratory quality: Even an approved diagnostic product can produce unreliable results if laboratory procedures are inadequate.

6. Emergency diagnostics: Public-health emergencies require rapid access to reliable testing without compromising patient safety.

7. Post-market surveillance: Regulators must identify defective products and respond to false results, adverse incidents and manufacturing failures.

12. Recommendations for strengthening Moroccan diagnostic regulation

The following reforms could improve the regulatory framework:

Establish clearer classification rules for advanced diagnostic technologies.

Strengthen independent laboratory performance testing.

Improve transparency in registration decisions.

Develop specific regulatory guidance for AI-based diagnostic systems.

Strengthen post-market surveillance and product-recall mechanisms.

Improve cooperation between foreign manufacturers and Moroccan importers.

Introduce stronger safeguards for genetic and personal medical data.

Encourage international cooperation in diagnostic-device evaluation.

13. Conclusion

Regulatory approval for diagnostic tools is a fundamental element of Moroccan biotechnology and healthcare governance.

Law No. 11-08 provides the framework for in-vitro diagnostic reagents, while Law No. 84-12 regulates medical devices. Their implementing decrees and administrative requirements establish the procedures for registration, technical assessment, market access and continuing oversight.

The Casablanca Commercial Court of Appeal decision of 13 December 2022, together with the Court of Cassation's decision of 9 June 2022, provides important judicial guidance concerning registration responsibilities for imported medical devices.

The central legal principle is that diagnostic products must satisfy the regulatory requirements applicable to their category before lawful commercial marketing. Approval must be accompanied by continuing quality control, scientific reliability and patient protection.

Ultimately, an effective regulatory framework must balance biotechnology innovation, commercial accessibility, scientific evidence and the fundamental right to safe healthcare.

14. Important legal references for academic research

Moroccan Law No. 11-08 concerning in-vitro diagnostic reagents.

Decree No. 2-12-149 implementing Law No. 11-08.

Moroccan Law No. 84-12 concerning medical devices.

Decree No. 2-14-607 implementing Law No. 84-12.

Moroccan Law No. 17-04 concerning medicines and pharmacy.

Moroccan Law No. 12-01 concerning private medical biology laboratories.

Casablanca Court of Appeal of Commerce, Decision No. 5633, 13 December 2022.

Moroccan Court of Cassation, Decision No. 383/1, 9 June 2022.

Boston Scientific, CJEU, Joined Cases C-503/13 and C-504/13 (2015).

Medipac-Kazantzidis, CJEU, Case C-6/05 (2007).

Official research resources:

Moroccan Ministry of Health – Regulatory legislation

AMMPS – Diagnostic reagent registration and regulatory information

Moroccan medical laboratory legislation

Academic note: The Moroccan decisions discussed above concern medical-device registration and commercial responsibility, not a direct judicial ruling on IVD diagnostic-kit approval. The European cases are comparative authorities and should not be presented as binding Moroccan precedents.